For research use only. Not for therapeutic Use.
Cefepime Dihydrochloride Monohydrate(Cat No.:I000910)is a fourth-generation cephalosporin antibiotic known for its broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including resistant strains like Pseudomonas aeruginosa. It functions by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Cefepime is commonly used to treat severe infections such as pneumonia, urinary tract infections, and intra-abdominal infections, as well as febrile neutropenia in immunocompromised patients. Its resistance to many beta-lactamases makes it a valuable option for treating complicated hospital-acquired infections, ensuring effective outcomes in critical care settings.
Catalog Number | I000910 |
CAS Number | 123171-59-5 |
Molecular Formula | C19H25ClN6O5S2 HCl H2O |
Purity | ≥95% |
Target | Antibacterial |
Solubility | 10 mM in H2O |
Storage | Store at -20°C |
IUPAC Name | (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride;hydrate;hydrochloride |
InChI | InChI=1S/C19H24N6O5S2.2ClH.H2O/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11;;;/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29);2*1H;1H2/b23-12-;;;/t13-,17-;;;/m1.../s1 |
InChIKey | LRAJHPGSGBRUJN-OMIVUECESA-N |
SMILES | C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)O.O.Cl.[Cl-] |
Reference | </br>1:Identification and characterization of new degradation products of cefepime dihydrochloride monohydrate drug substance during stress stability studies. Jagadeesh Kumar V, Badarinadh Gupta P, Pavan Kumar KS, Prasada Rao KV, Rao KR, Prasanna SJ, Kumar Sharma H, Mukkanti K.Anal Sci. 2010;26(10):1081-6. PMID: 20953052 Free Article</br>2:Stability of cefepime dihydrochloride monohydrate in solid state. Musiał W, Zajac M.Acta Pol Pharm. 2002 Jul-Aug;59(4):243-6. PMID: 12403297 Free Article |